1. Home
  2. NUVL vs AXTA Comparison

NUVL vs AXTA Comparison

Compare NUVL & AXTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$105.83

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo Axalta Coating Systems Ltd.

AXTA

Axalta Coating Systems Ltd.

HOLD

Current Price

$33.22

Market Cap

7.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
AXTA
Founded
2017
1910
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Paints/Coatings
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
7.2B
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
NUVL
AXTA
Price
$105.83
$33.22
Analyst Decision
Strong Buy
Buy
Analyst Count
15
14
Target Price
$135.00
$36.36
AVG Volume (30 Days)
548.0K
3.5M
Earning Date
02-26-2026
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
40.67
EPS
N/A
2.09
Revenue
N/A
$5,166,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2.01
P/E Ratio
N/A
$16.05
Revenue Growth
N/A
N/A
52 Week Low
$55.54
$26.28
52 Week High
$112.88
$38.37

Technical Indicators

Market Signals
Indicator
NUVL
AXTA
Relative Strength Index (RSI) 54.70 63.43
Support Level $97.43 $31.61
Resistance Level $108.65 $33.61
Average True Range (ATR) 4.95 0.60
MACD 0.48 -0.05
Stochastic Oscillator 82.96 79.21

Price Performance

Historical Comparison
NUVL
AXTA

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About AXTA Axalta Coating Systems Ltd.

Axalta Coating Systems Ltd is a manufacturer, marketer and distributor of high-performance coatings systems. It operates in two segments, The Performance Coatings segment provides liquid and powder coatings solutions to a fragmented and local customer base. Its end markets include refinish and industrial. The Mobility Coatings segment relates to the provision of coating technologies to original equipment manufacturers of light and commercial vehicles. The company operates in the geographic areas of North America, EMEA countries, Asia-Pacific, and Latin America.

Share on Social Networks: